Is BIOMARIN PHARMACEUTICAL INC (BMRN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.2% / 30% | 13.3% / 30% | 7.7% / 30% | 2.33% / 5% | ✓ HALAL |
| DJIM | 5.2% / 33% | 13.3% / 33% | 7.7% / 33% | 2.33% / 5% | ✓ HALAL |
| MSCI | 8.0% / 33% | 20.6% / 33% | 12.0% / 33% | 2.33% / 5% | ✓ HALAL |
| S&P | 5.2% / 33% | 13.3% / 33% | 7.7% / 33% | 2.33% / 5% | ✓ HALAL |
| FTSE | 8.0% / 33% | 20.6% / 33% | 12.0% / 50% | 2.33% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 52.8% | |
| Operating Margin | 22.5% | |
| Net Margin | 10.8% | |
| Return on Equity (ROE) | 5.9% | |
| Return on Assets (ROA) | 5.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $828M |
| Free Cash Flow | $717M |
| Total Debt | $606M |
| Debt-to-Equity | 10.6 |
| Current Ratio | 5.2 |
| Total Assets | $7.6B |
Price & Trading
| Last Close | $55.55 |
| 50-Day MA | $58.35 |
| 200-Day MA | $56.55 |
| Avg Volume | 2.2M |
| Beta | 0.3 |
|
52-Week Range
$50.76
| |
About BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Purification Calculator
As a halal stock with 2.33% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BIOMARIN PHARMACEUTICAL INC (BMRN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BIOMARIN PHARMACEUTICAL INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BIOMARIN PHARMACEUTICAL INC's debt ratio?
BIOMARIN PHARMACEUTICAL INC's debt ratio is 5.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.0%.
Does BIOMARIN PHARMACEUTICAL INC require dividend purification?
Yes, BIOMARIN PHARMACEUTICAL INC has an impermissible income ratio of 2.33%, which means 2.33% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are BIOMARIN PHARMACEUTICAL INC's key financial metrics?
BIOMARIN PHARMACEUTICAL INC has a market capitalization of $10.4B, trailing P/E ratio of 30.1, and revenue of $3.2B. The company maintains a gross margin of 52.8% and a net margin of 10.8%. Return on equity stands at 5.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.